GlobeNewswire·May 21, 2026, 6:30 AM ET

Immix Biopharma Announces Pricing of $150 Million Underwritten Offering of Common Stock

Immix Biopharma, Inc. priced an underwritten registered offering of 16,778,524 common shares at $8.94 per share.
Gross proceeds from the offering are expected to total $150 million before deducting underwriting discounts, commissions, and expenses.
The offering is scheduled to close on or about May 22, 2026, subject to customary closing conditions.
Net proceeds will fund NXC-201 development, working capital, and general corporate purposes.
The company believes existing cash & proceeds will support operational needs through mid-2028.
Morgan Stanley serves as lead book-running manager, with BofA Securities as book-running manager.
LifeSci Capital, Mizuho, and Needham & Company act as co-lead managers for the transaction.
The securities were offered under a Form S-3 shelf registration statement filed with the SEC on January 9, 2026.
NXC-201 is a sterically-optimized BCMA-targeted CAR-T therapy currently in the NEXICART-2 study for relapsed/refractory AL Amyloidosis.
NXC-201 holds Breakthrough Therapy, RMAT, Orphan Drug, & EU Orphan Drug designations from the FDA & EMA.